- Home
- MTZ vs PCVX Comparison
MTZ vs PCVX Comparison
Compare MTZ & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTZ | PCVX |
|---|---|---|
| Founded | 1929 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0B | 7.0B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MTZ | PCVX |
|---|---|---|
| Price | $190.19 | $63.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 11 |
| Target Price | ★ $386.10 | $117.30 |
| AVG Volume (30 Days) | 1.4M | ★ 3.2M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.12 | N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $14,299,171,000.00 | N/A |
| Revenue This Year | $27.25 | N/A |
| Revenue Next Year | $18.21 | N/A |
| P/E Ratio | $79.14 | ★ N/A |
| Revenue Growth | ★ 16.22 | N/A |
| 52 Week Low | $182.34 | $39.87 |
| 52 Week High | $441.43 | $90.75 |
Technical Indicators
Market Signals| Indicator | MTZ | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 30.41 | 50.37 |
| Support Level | N/A | $50.26 |
| Resistance Level | $250.78 | $90.75 |
| Average True Range (ATR) | 8.86 | 4.96 |
| MACD | -0.85 | 0.13 |
| Stochastic Oscillator | 14.66 | 21.57 |
Price Performance
Historical ComparisonAbout MTZ MasTec Inc.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; pipeline infrastructure; power delivery; and other.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.